It is motivated by stable chronic heart failure (CHF) patients who are periodically seen to assess the risk of disease aggravation based on multiple patient characteristics and circulating marker protein levels such as NT‐proBNP and troponin. The gene discussed is NPPB; the disease is congestive heart failure.